Moleculin Biotech, Inc. (MBRX)
7.90
-0.82
(-9.40%)
USD |
NASDAQ |
Oct 30, 16:00
8.10
+0.20
(+2.53%)
After-Hours: 20:00
Moleculin Biotech Enterprise Value : -4.166M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | -4.166M |
| October 29, 2026 | -3.874M |
| October 28, 2026 | -3.866M |
| October 27, 2026 | -3.681M |
| October 26, 2026 | -4.455M |
| October 23, 2026 | -4.662M |
| October 22, 2026 | -4.879M |
| October 21, 2026 | -4.73M |
| October 20, 2026 | -4.773M |
| October 19, 2026 | -5.088M |
| October 16, 2026 | -4.979M |
| October 15, 2026 | -4.342M |
| October 14, 2026 | -4.052M |
| October 13, 2026 | -3.880M |
| October 12, 2026 | -4.031M |
| October 09, 2026 | -3.832M |
| October 08, 2026 | -3.960M |
| October 07, 2026 | -3.854M |
| October 06, 2026 | -3.807M |
| October 05, 2026 | -3.586M |
| October 02, 2026 | -3.514M |
| October 01, 2026 | -3.393M |
| September 30, 2026 | -3.417M |
| September 29, 2026 | -3.233M |
| September 28, 2026 | -2.930M |
| Date | Value |
|---|---|
| September 25, 2026 | -2.699M |
| September 24, 2026 | -2.945M |
| September 23, 2026 | -3.222M |
| September 22, 2026 | -2.958M |
| September 21, 2026 | -3.277M |
| September 18, 2026 | -1.481M |
| September 17, 2026 | -1.432M |
| September 16, 2026 | -1.716M |
| September 15, 2026 | -1.634M |
| September 14, 2026 | -1.466M |
| September 11, 2026 | -1.894M |
| September 10, 2026 | -1.078M |
| September 09, 2026 | -1.538M |
| September 08, 2026 | -1.644M |
| September 04, 2026 | -1.930M |
| September 03, 2026 | -2.174M |
| September 02, 2026 | -2.043M |
| September 01, 2026 | -2.355M |
| August 31, 2026 | -2.393M |
| August 28, 2026 | -2.356M |
| August 27, 2026 | -2.080M |
| August 26, 2026 | -2.71M |
| August 25, 2026 | -2.632M |
| August 24, 2026 | -2.644M |
| August 21, 2026 | -2.760M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.662B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 267.21M |
| Savara, Inc. | 847.40M |
| Vericel Corp. | 1.992B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.635M |
| Total Expenses (Quarterly) | 7.635M |
| EPS Diluted (Quarterly) | -28.04 |
| Earnings Yield | -4.34K% |
| Normalized Earnings Yield | -3760.45 |